hypothyroidism and tirzepatide thyroid function in adults with type 2 diabetes or obesity: a systematic evidence map and data gap analysis Implications of GLP-1 Receptor Agonist

First 3-6 months: close monitoring phase The dose-escalation period is when most side effects emerge and when your body adjusts to the medication

Others deal with side effects that meaningfully affect daily life

In a recent head to head, tirzepatide demonstrated superior weight loss benefits, showing 20.2% average weight loss vs

After about four weeks of consistent weekly dosing, your body reaches what pharmacologists call "steady state," the point where the amount of drug entering your system each week equals the amount leaving

Zepbound injections are suitable for individuals with a body mass index (BMI) of 27 or higher who have weight-related health conditions such as obesity or type 2 diabetes